Beam Therapeutics: A Valuation With Upside Left (NASDAQ:BEAM)
· seekingalpha.com
Beam Therapeutics (BEAM) stock outlook: gene-editing pipeline, strong cash runway to 2029, and conservative valuation.
Max is an independent equity research analyst with a primary focus on biotechnology, healthcare, and technology companies. His investment approach is fundamenta...